Lead Counsel Appointed in Zantac Litigation
LegalShield Referral Firm Appointed Lead Counsel in Zantac Litigation
We congratulate our long time referral attorney partners at the Philadelphia law firm of Anapol Weiss. U.S. District Judge Robin Rosenberg of the Southern District of Florida appointed the Anapol Weiss firm as co-lead counsel to spearhead the hundreds of lawsuits filed over heartburn medication Zantac.
If you are currently taking Zantac, you should discuss the potential risks with your health care provider. You may be entitled to monetary damages. Contact us for a consultation about your situation.
The lawsuits, both individual cases alleging personal injuries and class actions brought for economic damages, allege that the companies that made and sold Zantac knew its active ingredient, ranitidine, metabolized in the human body to form a carcinogen known as N-nitrosodimethylamine, or NDMA.
The lawsuits follow the U.S. Food and Drug Administration’s investigation of NDMA in some blood pressure and heart failure medicines. Last month, the FDA announced it was requesting manufacturers to withdraw all prescription and over-the-counter Zantac from the market, citing concerns about potential carcinogens.
Sanofi-Aventis U.S., based in New Jersey, which recalled over-the-counter Zantac last year, is one of several defendants in the cases. Others are GlaxoSmithKline, with a U.S. unit based in Philadelphia, which first received FDA approval to sell the drug and recalled prescription Zantac last year, and Boehringer Ingelheim Pharmaceuticals Inc., which has U.S. headquarters in Connecticut, and New York’s Pfizer Inc. They both sold Zantac.